In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...
The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...
The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...
A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...
Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors.
A significant portion of the clinical management for ADCs involves addressing payload-dependent toxicities, with interstitial lung disease (ILD) being a notable safety concern and potentially serious ...
During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results